CBGD
MCID: CRT033
MIFTS: 57

Corticobasal Degeneration (CBGD)

Categories: Muscle diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Corticobasal Degeneration

MalaCards integrated aliases for Corticobasal Degeneration:

Name: Corticobasal Degeneration 52 53 29 71
Corticobasal Syndrome 52 58 6
Cortical-Basal Ganglionic Degeneration 52
Cortico-Basal Ganglionic Degeneration 52
Cbgd 52

Classifications:

Orphanet: 58  
Rare neurological diseases


Summaries for Corticobasal Degeneration

NINDS : 53 Corticobasal degeneration is a progressive neurological disorder characterized by nerve cell loss and atrophy (shrinkage) of multiple areas of the brain including the cerebral cortex and the basal ganglia. Corticobasal degeneration progresses gradually. Initial symptoms, which typically begin at or around age 60, may first appear on one side of the body (unilateral), but eventually affect both sides as the disease progresses. Symptoms are similar to those found in Parkinson disease, such as poor coordination, akinesia (an absence of movements), rigidity (a resistance to imposed movement),disequilibrium (impaired balance); and limb dystonia (abnormal muscle postures). Other symptoms such as cognitive and visual-spatial impairments, apraxia (loss of the ability to make familiar, purposeful movements), hesitant and halting speech, myoclonus (muscular jerks), and dysphagia (difficulty swallowing) may also occur. An individual with corticobasal degeneration eventually becomes unable to walk.

MalaCards based summary : Corticobasal Degeneration, also known as corticobasal syndrome, is related to frontotemporal lobar degeneration with tdp43 inclusions, grn-related and leukoencephalopathy, hereditary diffuse, with spheroids. An important gene associated with Corticobasal Degeneration is MAPT (Microtubule Associated Protein Tau), and among its related pathways/superpathways are NFAT and Cardiac Hypertrophy and Human cytomegalovirus infection. The drugs Iodine and Pharmaceutical Solutions have been mentioned in the context of this disorder. Affiliated tissues include brain, cortex and testes, and related phenotypes are parkinsonism and progressive extrapyramidal muscular rigidity

NIH Rare Diseases : 52 Corticobasal degeneration is characterized by the break down (degeneration) of parts of the brain, including the cerebral cortex and basal ganglia. The cerebral cortex is responsible for most of the brain's processing of information, and the basal ganglia are deep brain structures that help start and control movement. Signs and symptoms of corticobasal degeneration include poor coordination, loss of movement, rigidity, poor balance, unnatural posturing of the muscles, intellectual (cognitive) impairment, speech impairment, muscular jerks, and difficulty swallowing. These symptoms develop and worsen over time. Currently the cause of corticobasal degeneration is not known. Treatment depends on the symptoms in each person. People with corticobasal degeneration usually do not survive beyond an average of 7 years after symptoms begin. Aspiration pneumonia or other complications are usually the cause of death.

Wikipedia : 74 Corticobasal degeneration (CBD) is a rare, neurodegenerative disease involving the cerebral cortex and... more...

Related Diseases for Corticobasal Degeneration

Diseases related to Corticobasal Degeneration via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 184)
# Related Disease Score Top Affiliating Genes
1 frontotemporal lobar degeneration with tdp43 inclusions, grn-related 33.2 RPS27A MAPT
2 leukoencephalopathy, hereditary diffuse, with spheroids 32.9 RPS27A MAPT CRYAB
3 semantic dementia 32.6 TARDBP RPS27A MAPT
4 pick disease of brain 31.9 TARDBP RPS27A MOBP MAPT LRRK2 CRYAB
5 supranuclear palsy, progressive, 1 31.8 TARDBP RPS27A MOBP MAPT LRRK2 GBA
6 frontotemporal dementia 31.7 TARDBP RPS27A MOBP MAPT LRRK2 CRYAB
7 aphasia 31.2 TARDBP MAPT LRRK2
8 tremor 31.2 MAPT LRRK2 GBA
9 multiple system atrophy 1 31.1 RPS27A MAPT LRRK2
10 ideomotor apraxia 31.1 TARDBP MAPT
11 movement disease 30.4 TARDBP MAPT LRRK2 GBA
12 agraphia 30.4 TARDBP MAPT
13 rem sleep behavior disorder 30.4 RPS27A MAPT LRRK2 GBA
14 dysgraphia 30.4 TARDBP MAPT
15 akinetic mutism 30.4 TARDBP MAPT
16 essential tremor 30.1 MAPT LRRK2 GBA
17 motor neuron disease 30.1 UCHL1 TARDBP RPS27A MAPT
18 nominal aphasia 30.0 TARDBP MAPT
19 dementia 30.0 UCHL1 TARDBP RPS27A MAPT LRRK2 GBA
20 postencephalitic parkinson disease 29.9 TARDBP MAPT LRRK2
21 parkinson disease, late-onset 29.4 UCHL1 RPS27A PITX3 MTOR MAPT LRRK2
22 dementia, lewy body 29.2 UCHL1 TARDBP RPS27A MAPT LRRK2 GBA
23 amyotrophic lateral sclerosis 1 29.1 UCHL1 TARDBP RPS27A MAPT LRRK2 HSPB2
24 alzheimer disease 29.1 UCHL1 TARDBP RPS6KB1 RPS27A MTOR MAPT
25 progressive supranuclear palsy-corticobasal syndrome 12.4
26 grn-related frontotemporal lobar degeneration 11.5
27 apraxia 11.0
28 myoclonus 10.9
29 dystonia 10.8
30 spinal muscular atrophy type 0 10.5 RPS27A MAPT
31 cerebral atrophy 10.5
32 cerebral cortical dysplasia 10.5 RPS27A MAPT
33 creutzfeldt-jakob disease 10.4
34 argyria 10.4
35 dysphagia 10.4
36 spasticity 10.4
37 kearns-sayre syndrome 10.3
38 mutism 10.3
39 focal dystonia 10.3
40 lateral sclerosis 10.3
41 progressive non-fluent aphasia 10.3
42 rare neurodegenerative disease 10.3
43 ataxia and polyneuropathy, adult-onset 10.3
44 hereditary late-onset parkinson disease 10.3 LRRK2 GBA
45 early-onset posterior polar cataract 10.2 PITX3 CRYAB
46 parkinson disease 1, autosomal dominant 10.2 LRRK2 GBA
47 parkinson disease 3, autosomal dominant 10.2 UCHL1 MAPT LRRK2
48 respiratory failure 10.2
49 posterior cortical atrophy 10.2
50 gait apraxia 10.2

Graphical network of the top 20 diseases related to Corticobasal Degeneration:



Diseases related to Corticobasal Degeneration

Symptoms & Phenotypes for Corticobasal Degeneration

Human phenotypes related to Corticobasal Degeneration:

58 31 (show all 23)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 parkinsonism 58 31 hallmark (90%) Very frequent (99-80%) HP:0001300
2 progressive extrapyramidal muscular rigidity 58 31 hallmark (90%) Very frequent (99-80%) HP:0007158
3 gait disturbance 58 31 frequent (33%) Frequent (79-30%) HP:0001288
4 tremor 58 31 frequent (33%) Frequent (79-30%) HP:0001337
5 sensory impairment 58 31 frequent (33%) Frequent (79-30%) HP:0003474
6 dementia 58 31 frequent (33%) Frequent (79-30%) HP:0000726
7 limb dystonia 58 31 frequent (33%) Frequent (79-30%) HP:0002451
8 akinesia 58 31 frequent (33%) Frequent (79-30%) HP:0002304
9 postural instability 58 31 frequent (33%) Frequent (79-30%) HP:0002172
10 bradykinesia 58 31 frequent (33%) Frequent (79-30%) HP:0002067
11 limb apraxia 58 31 frequent (33%) Frequent (79-30%) HP:0030217
12 oromotor apraxia 58 31 frequent (33%) Frequent (79-30%) HP:0007301
13 limb myoclonus 58 31 frequent (33%) Frequent (79-30%) HP:0045084
14 frontal release signs 58 31 frequent (33%) Frequent (79-30%) HP:0000743
15 dysphasia 58 31 occasional (7.5%) Occasional (29-5%) HP:0002357
16 memory impairment 58 31 occasional (7.5%) Occasional (29-5%) HP:0002354
17 speech apraxia 58 31 occasional (7.5%) Occasional (29-5%) HP:0011098
18 aphasia 58 31 occasional (7.5%) Occasional (29-5%) HP:0002381
19 behavioral abnormality 58 31 very rare (1%) Very rare (<4-1%) HP:0000708
20 myoclonus 58 Very frequent (99-80%)
21 abnormality of movement 58 Very rare (<4-1%)
22 involuntary movements 58 Frequent (79-30%)
23 dystonia 58 Occasional (29-5%)

GenomeRNAi Phenotypes related to Corticobasal Degeneration according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability with paclitaxel GR00179-A-1 9.02 MTOR RPS6KB1
2 Decreased viability with paclitaxel GR00179-A-2 9.02 MTOR
3 Decreased viability with paclitaxel GR00179-A-3 9.02 MTOR RPS6KB1

MGI Mouse Phenotypes related to Corticobasal Degeneration:

45 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.32 CFL1 CRYAB GBA HSPB2 KIF13B LRRK2
2 cellular MP:0005384 10.32 CFL1 CRYAB GBA HSPB2 KIF13B LRRK2
3 cardiovascular system MP:0005385 10.27 CFL1 GBA HSPB2 LRRK2 MAPT MTOR
4 homeostasis/metabolism MP:0005376 10.25 CFL1 CRYAB GBA KIF13B LRRK2 MAPT
5 growth/size/body region MP:0005378 10.23 CFL1 GBA KIF13B MAPT MTOR PITX3
6 hematopoietic system MP:0005397 10.21 CSF3 GBA KIF13B LRRK2 MAPT MTOR
7 immune system MP:0005387 10.15 CSF3 GBA KIF13B LRRK2 MAPT MTOR
8 integument MP:0010771 9.97 CFL1 CSF3 GBA LRRK2 MAPT PITX3
9 nervous system MP:0003631 9.93 CFL1 GBA LRRK2 MAPT MOBP MTOR
10 muscle MP:0005369 9.86 CRYAB MAPT MTOR ROCK1 ROCK2 RPS6KB1
11 no phenotypic analysis MP:0003012 9.5 CFL1 KIF13B LRRK2 MAPT MTOR PITX3
12 renal/urinary system MP:0005367 9.17 CFL1 CSF3 LRRK2 MAPT MTOR ROCK1

Drugs & Therapeutics for Corticobasal Degeneration

Drugs for Corticobasal Degeneration (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 50)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Iodine Approved, Investigational Phase 4 7553-56-2 807
2 Pharmaceutical Solutions Phase 4
3 Calamus Phase 4
4 cadexomer iodine Phase 4
5
Pimavanserin Approved, Investigational Phase 3 706779-91-1 16058810
6
Coenzyme Q10 Approved, Investigational, Nutraceutical Phase 2, Phase 3 303-98-0 5281915
7 Trace Elements Phase 2, Phase 3
8 Vitamins Phase 2, Phase 3
9 Nutrients Phase 2, Phase 3
10 Micronutrients Phase 2, Phase 3
11 Ubiquinone Phase 2, Phase 3
12 Psychotropic Drugs Phase 3
13 Antiparkinson Agents Phase 3
14 Antipsychotic Agents Phase 3
15
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
16
Lithium carbonate Approved Phase 1, Phase 2 554-13-2
17
Dopamine Approved Phase 2 51-61-6, 62-31-7 681
18
Memantine Approved, Investigational Phase 2 19982-08-2 4054
19
Carvedilol Approved, Investigational Phase 2 72956-09-3 2585
20
Vitamin A Approved, Nutraceutical, Vet_approved Phase 2 22737-96-8, 68-26-8, 11103-57-4 9904001 445354
21 Antidepressive Agents Phase 1, Phase 2
22 Fluorodeoxyglucose F18 Phase 2
23 Radiopharmaceuticals Phase 2
24 Dopamine Agents Phase 2
25 Excitatory Amino Acid Antagonists Phase 2
26 Neurotransmitter Agents Phase 2
27 Adrenergic beta-Antagonists Phase 2
28 Adrenergic alpha-Antagonists Phase 2
29 Antihypertensive Agents Phase 2
30 Antioxidants Phase 2
31 Adrenergic Agents Phase 2
32 Retinol palmitate Phase 2
33 retinol Phase 2
34 Hormones Phase 2
35 Adrenergic Antagonists Phase 2
36 Vasodilator Agents Phase 2
37 Protective Agents Phase 2
38 Adrenergic alpha-1 Receptor Antagonists Phase 2
39 Calcium, Dietary Phase 2
40 calcium channel blockers Phase 2
41
Calcium Nutraceutical Phase 2 7440-70-2 271
42 taxane Phase 1
43 Tubulin Modulators Phase 1
44 Immunoglobulins Phase 1
45 Antibodies Phase 1
46 Antibodies, Monoclonal Phase 1
47 Vaccines
48 ABBV-8E12
49 Deoxyglucose
50
Leucine Investigational, Nutraceutical 61-90-5 6106

Interventional clinical trials:

(show all 36)
# Name Status NCT ID Phase Drugs
1 Longitudinal Multi-Modality Imaging in Progressive Apraxia of Speech Recruiting NCT01818661 Phase 4 AV-1451
2 DaTSCAN Imaging in Aging and Neurodegenerative Disease Enrolling by invitation NCT01453127 Phase 4 I-123 Ioflupane solution injection prior to SPECT scan (DaTscan)
3 Effects of Coenzyme Q10 in PSP and CBD, A Randomized, Placebo-Controlled, Double Blind Cross Over Pilot Study Completed NCT00532571 Phase 2, Phase 3 CoQ10
4 A Double-blind, Placebo-controlled, Relapse Prevention Study of Pimavanserin for the Treatment of Hallucinations and Delusions Associated With Dementia-related Psychosis Completed NCT03325556 Phase 3 Placebo;Pimavanserin 34 mg;Pimavanserin 20 mg
5 Novel Neuroimage Study in Tauopathies With Parkinsonism Unknown status NCT03386669 Phase 2 F-18
6 A Pilot Trial of Lithium in Subjects With Progressive Supranuclear Palsy or Corticobasal Degeneration Completed NCT00703677 Phase 1, Phase 2 Lithium
7 The Differential Diagnosis of Parkinson's Disease and Parkinsonism by Positron-emission Tomography With Vesicular Monoamine Transporter Ligand (18F-DTBZ) Completed NCT01824056 Phase 2 18F-FDG
8 Direct Current Brain Polarization for Apraxia in Corticobasal Syndrome Completed NCT00273897 Phase 2
9 Double-blind, Parallel Group, Placebo-controlled Trial of the Efficacy and Tolerability of Memantine (20 mg) in Frontotemporal Dementia (FTD) Patients Completed NCT00200538 Phase 2 memantine
10 The Effect of Adrenergic Blocker Therapy on Cardiac and Striatal Transporter Uptake in Pre-Motor and Symptomatic Parkinson's Disease Recruiting NCT03775096 Phase 2 Carvedilol
11 A Noval Tau Tracer ([18F]PM-PBB3) in Young Onset Dementia: Clinical and Neuroimaging Study Not yet recruiting NCT04248270 Phase 1, Phase 2 18F-PM-PBB3
12 A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Sequential Cohort, Dose-Ranging Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of TPI 287 in Patients With Primary Four Repeat Tauopathies: Corticobasal Syndrome or Progressive Supranuclear Palsy Completed NCT02133846 Phase 1 TPI 287 2 mg/m2;TPI-287 20 mg/m2;Placebo;TPI-287 6.3 mg/m2
13 18F-AV-1451 Injection for Brain Imaging of Tau in Subjects With Progressive Supranuclear Palsy (PSP), Subjects With Corticobasal Degeneration (CBD) and Healthy Volunteers" Completed NCT02167594 Phase 1 18F-AV-1451;florbetapir F18
14 A 12 Week Randomized, Double Blind, Placebo-Controlled Pilot Study of Davunetide (NAP, AL-108) in Predicted Tauopathies Completed NCT01056965 Phase 1 davunetide (AL-108, NAP);Placebo nasal spray
15 Alzheimer's PET Imaging in Racially/Ethnically Diverse Adults Recruiting NCT03706261 Phase 1 18F-MK-6240;18F-Florbetaben
16 A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Parallel Cohort Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy Study of Intravenously Infused BIIB092 in Patients With Four Different Primary Tauopathy Syndromes Terminated NCT03658135 Phase 1 BIIB092
17 Observational Study Assessing the Diagnostic Contribution of 3-Tesla MRI, CSF Analysis and a Second Opinion in a Specialized Movement Disorder Centre, in Differentiating Between Parkinson's Disease and Atypical Parkinsonism Unknown status NCT01249768
18 Innovative Biomarkers in Alzheimer's Disease and Frontotemporal Dementia (FTD): Preventative and Personalized Unknown status NCT01403519
19 Noninvasive Cortical Stimulation (rTMS) for Motor and Non-Motor Features of Progressive Supranuclear Palsy (PSP) and Corticobasal Degeneration (CBD) Completed NCT01174771
20 Vaccination Uptake in Parkinson's Disease Completed NCT02874274
21 Effect of Task on Oral Pressure Dynamics During Swallowing Completed NCT00013832
22 The Four-Repeat Tauopathy Neuroimaging Initiative Recruiting NCT02966145
23 Human CNS Tau Kinetics in Tauopathies Recruiting NCT03545126
24 Smell, Voice and Nasal Swabs as Markers for Neuro-degenerative Disorders Recruiting NCT03299062
25 Multimodal Assessment For Predicting Specific Pathological Substrate in Frontotemporal Lobar Degeneration Recruiting NCT02964637
26 Assessing Changes in Social Cognition and Personality in Patients With Frontotemporal Lobar Degeneration, Alzheimer's Disease and Parkinson's Disease and Their Effect on the Patient-caregiver Relationship Recruiting NCT02964611
27 Rare Diseases Clinical Research Network Advancing Research and Treatment for Frontotemporal Lobar Degeneration [ARTFL]: Research Projects 1 & 2 Recruiting NCT02365922
28 Investigating Complex Neurodegenerative Disorders Related to Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Recruiting NCT03225144
29 More Than a Movement Disorder: Applying Palliative Care to Parkinson's Disease Recruiting NCT03076671
30 CNS Tau Kinetics in Healthy Aging and Alzheimer's Disease Recruiting NCT03938870
31 Observational Longitudinal Study of Magnetic Resonance Imaging, Specimen Biomarkers, and Clinical Progression in Progressive Supranuclear Palsy and Corticobasal Degeneration Active, not recruiting NCT01804452
32 PDx Biomarker Assay Study for the Diagnosis of Parkinson's Disease Active, not recruiting NCT02283073
33 Defining Cognitive and Motor Phenotypes of Parkinson's Disease (PD) With Magnetoencephalography Active, not recruiting NCT02132052
34 Positron Emission Tomography (PET) Imaging of Tau Pathology in Neurodegenerative Disease Active, not recruiting NCT03143374
35 Expanded Access to ABBV-8E12 No longer available NCT03744546 ABBV-8E12
36 Regional Cerebral Utilization of Glucose in Patients With a Diagnosis of Frontal Lobe Dementia, Atypical Parkinsonian Disorder, and Other Basal Ganglia Disorders Terminated NCT00001178

Search NIH Clinical Center for Corticobasal Degeneration

Genetic Tests for Corticobasal Degeneration

Genetic tests related to Corticobasal Degeneration:

# Genetic test Affiliating Genes
1 Corticobasal Degeneration 29

Anatomical Context for Corticobasal Degeneration

MalaCards organs/tissues related to Corticobasal Degeneration:

40
Brain, Cortex, Testes, Eye, Spinal Cord, Temporal Lobe, Cerebellum

Publications for Corticobasal Degeneration

Articles related to Corticobasal Degeneration:

(show top 50) (show all 1896)
# Title Authors PMID Year
1
Is brain perfusion a differentiating feature in the comparison of Progressive Supranuclear Palsy Syndrome (PSPS) and Corticobasal Syndrome (CBS)? 61
32389545 2020
2
Serum neuronal exosomes predict and differentiate Parkinson's disease from atypical parkinsonism. 61
32273329 2020
3
Targeting tau: Clinical trials and novel therapeutic approaches. 61
32380145 2020
4
Binding of [18F]AV1451 in post mortem brain slices of semantic variant primary progressive aphasia patients. 61
31848674 2020
5
Corticobasal degeneration with deep white matter lesion diagnosed by brain biopsy. 61
31925842 2020
6
Proactive interference apraxic agraphia: a writing and drawing disorder associated with corticobasal syndrome. 61
32323627 2020
7
Corticobasal Degeneration Reveals Its Signature by Tau Strains. 61
32259299 2020
8
Individual Brain Metabolic Signatures in Corticobasal Syndrome. 61
32538847 2020
9
Hydration and Dynamics of Full-Length Tau Amyloid Fibrils Investigated by Solid-State Nuclear Magnetic Resonance. 61
32453948 2020
10
Neuropsychiatric Aspects of Frontotemporal Dementia. 61
32439026 2020
11
Frontotemporal Dementia: Neuropathology, Genetics, Neuroimaging, and Treatments. 61
32439025 2020
12
Cut-off scores of blink reflex recovery cycle to differentiate atypical parkinsonisms. 61
32526800 2020
13
Differential levels of Neurofilament Light protein in cerebrospinal fluid in patients with a wide range of neurodegenerative disorders. 61
32514050 2020
14
Clinical and pathologic features of cognitive-predominant corticobasal degeneration. 61
32518146 2020
15
Tau Ser208 phosphorylation promotes aggregation and reveals neuropathologic diversity in Alzheimer's disease and other tauopathies. 61
32571418 2020
16
Effect of Functional BDNF and COMT Polymorphisms on Symptoms and Regional Brain Volume in Frontotemporal Dementia and Corticobasal Syndrome. 61
32397876 2020
17
Redefining the multidimensional clinical phenotypes of frontotemporal lobar degeneration syndromes. 61
32438414 2020
18
Comparing two facets of emotion perception across multiple Neurodegenerative Diseases. 61
32363385 2020
19
Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. 61
32333900 2020
20
Amyloid PET in Dementia Syndromes: A Chinese Multicenter Study. 61
32385166 2020
21
Ioflupane 123I (DAT scan) SPECT identifies dopamine receptor dysfunction early in the disease course in progressive apraxia of speech. 61
32388831 2020
22
The importance of brain banking for dementia practice: the first experience of Turkey. 61
32435952 2020
23
Pick's disease: clinicopathologic characterization of 21 cases. 61
32440921 2020
24
Overview of sleep disturbances and their management in Parkinson plus disorders. 61
32446010 2020
25
Corticobasal syndrome-Pick's disease: A clinicopathological study. 61
32145523 2020
26
Alien limb in the corticobasal syndrome: phenomenological characteristics and relationship to apraxia. 61
31919566 2020
27
Pathology-Proven Corticobasal Degeneration Presenting as Richardson's Syndrome. 61
32258223 2020
28
Metabolomic changes associated with frontotemporal lobar degeneration syndromes. 61
32277260 2020
29
Tau Imaging in the 4-Repeat-Tauopathies Progressive Supranuclear Palsy and Corticobasal Syndrome: A 11C-Pyridinyl-Butadienyl-Benzothiazole 3 PET Pilot Study. 61
32108694 2020
30
Early-phase [18F]PI-2620 tau-PET imaging as a surrogate marker of neuronal injury. 61
32318783 2020
31
Fulminant corticobasal degeneration: a distinct variant with predominant neuronal tau aggregates. 61
31950334 2020
32
Novel tau filament fold in corticobasal degeneration. 61
32050258 2020
33
Early Impairment of Chopsticks Skills in Parkinsonism Suggests Progressive Supranuclear Palsy. 61
32319242 2020
34
[Characteristics of rare diseases in Zhejiang province, 2007-2017]. 61
32294843 2020
35
Confirmation of 123I-FP-CIT-SPECT (ioflupane) quantification methods in dementia with Lewy body and other neurodegenerative disorders. 61
32198310 2020
36
Progressive supranuclear palsy presenting with hyperkinetic movement disorder and hemiplegic dystonia: a case report. 61
32075473 2020
37
CSF sAPPα and sAPPβ levels in Alzheimer's Disease and Multiple Other Neurodegenerative Diseases: A Network Meta-Analysis. 61
31414383 2020
38
Cerebrospinal fluid levels of neurogranin in Parkinsonian disorders. 61
31837067 2020
39
Primary Tau Pathology, Not Copathology, Correlates With Clinical Symptoms in PSP and CBD. 61
31999351 2020
40
Human tau pathology transmits glial tau aggregates in the absence of neuronal tau. 61
31826239 2020
41
Chameleons and mimics: Progressive supranuclear palsy and corticobasal degeneration. 61
31515852 2020
42
Corrigendum to "Persistence of limb dystonia and myoclonus during sleep in corticobasal syndrome: a case series" [Sleep Med 59 (2019) 107-109]. 61
32008888 2020
43
Update on posterior cortical atrophy. 61
31688098 2020
44
Posttranslational Modifications Mediate the Structural Diversity of Tauopathy Strains. 61
32032505 2020
45
Neuropathology of Lewy body disease: Clinicopathological crosstalk between typical and atypical cases. 61
31498507 2020
46
Video research visits for atypical parkinsonian syndromes among Fox Trial Finder participants. 61
32190415 2020
47
Clinical Phenotypes in Corticobasal Syndrome with or without Amyloidosis Biomarkers. 61
32039846 2020
48
Levodopa-responsive parkinsonism in a patient with corticobasal degeneration and bilateral choroid plexus xanthogranulomas. 61
31537463 2020
49
"Tau Protein Targeting Via Radioiodinated Azure A For Brain Theranostics: Radiolabeling, Molecular Docking, in vitro And in vivo Biological Evaluation". 61
31785209 2020
50
Cortical laminar distribution of β-amyloid deposits in five neurodegenerative disorders. 61
32337952 2020

Variations for Corticobasal Degeneration

ClinVar genetic disease variations for Corticobasal Degeneration:

6 ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 TBK1 NM_013254.4(TBK1):c.2107G>T (p.Glu703Ter)SNV Likely pathogenic 619188 rs1565825132 12:64891788-64891788 12:64498008-64498008
2 ADAM10 NM_001110.4(ADAM10):c.359T>C (p.Ile120Thr)SNV Uncertain significance 870548 15:58971448-58971448 15:58679249-58679249
3 TTC3 NM_001320703.2(TTC3):c.5677G>A (p.Val1893Met)SNV Uncertain significance 870549 21:38568315-38568315 21:37196014-37196014

Expression for Corticobasal Degeneration

Search GEO for disease gene expression data for Corticobasal Degeneration.

Pathways for Corticobasal Degeneration

Pathways related to Corticobasal Degeneration according to GeneCards Suite gene sharing:

(show all 23)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.71 SOS1 RPS6KB1 ROCK2 ROCK1 MTOR
2
Show member pathways
12.71 SOS1 RPS6KB1 RPS27A ROCK2 ROCK1 MTOR
3 12.68 SOS1 RPS6KB1 ROCK2 ROCK1 MTOR
4 12.44 UCHL1 TARDBP RPS27A MAPT LRRK2
5
Show member pathways
12.42 SOS1 ROCK2 ROCK1 CFL1
6 12.39 ROCK2 ROCK1 MAPT CFL1
7
Show member pathways
12.36 SOS1 ROCK2 ROCK1 MTOR
8
Show member pathways
12.28 SOS1 RPS6KB1 ROCK2 ROCK1 MTOR
9
Show member pathways
12.26 ROCK2 ROCK1 MAPT CFL1
10
Show member pathways
12.22 SOS1 ROCK2 ROCK1 MAPT
11 12.19 RPS6KB1 RPS27A ROCK2 ROCK1 MTOR
12 11.94 RPS6KB1 MTOR MAPT CFL1
13 11.87 SOS1 RPS6KB1 ROCK1 MTOR CFL1
14 11.83 SOS1 RPS6KB1 MTOR
15
Show member pathways
11.53 SOS1 RPS6KB1 MTOR
16 11.41 SOS1 RPS6KB1 ROCK2 ROCK1 MTOR HSPB2
17 11.34 SOS1 RPS6KB1 ROCK2 ROCK1 MTOR
18 11.28 ROCK2 ROCK1 CFL1
19 11.28 SOS1 ROCK2 ROCK1 CFL1
20 11.15 SOS1 RPS6KB1 MTOR
21 11.07 RPS6KB1 ROCK2 ROCK1 CFL1
22
Show member pathways
10.8 RPS6KB1 MTOR
23 10.76 RPS6KB1 MTOR

GO Terms for Corticobasal Degeneration

Cellular components related to Corticobasal Degeneration according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytosol GO:0005829 9.83 UCHL1 SOS1 RPS6KB1 RPS27A ROCK2 ROCK1
2 axon GO:0030424 9.72 UCHL1 MAPT LRRK2 KIF13B CRYAB
3 neuronal cell body GO:0043025 9.63 UCHL1 SOS1 PITX3 MTOR MAPT LRRK2
4 mitochondrial outer membrane GO:0005741 9.56 RPS6KB1 RPS27A MTOR LRRK2
5 cytoplasm GO:0005737 9.55 UCHL1 TARDBP SOS1 RPS6KB1 RPS27A ROCK2

Biological processes related to Corticobasal Degeneration according to GeneCards Suite gene sharing:

(show all 36)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 10.04 RPS6KB1 RPS27A PRDX5 CRYAB CFL1
2 negative regulation of gene expression GO:0010629 9.96 TARDBP ROCK2 MAPT CRYAB
3 protein phosphorylation GO:0006468 9.85 RPS6KB1 ROCK2 ROCK1 MTOR LRRK2 CFL1
4 regulation of actin cytoskeleton organization GO:0032956 9.81 ROCK2 ROCK1 MTOR
5 negative regulation of protein phosphorylation GO:0001933 9.8 TARDBP MTOR LRRK2
6 regulation of cellular response to heat GO:1900034 9.8 MTOR MAPT CRYAB
7 Rho protein signal transduction GO:0007266 9.79 ROCK2 ROCK1 CFL1
8 cellular response to starvation GO:0009267 9.78 MTOR LRRK2 GBA
9 regulation of macroautophagy GO:0016241 9.75 UCHL1 MTOR GBA
10 I-kappaB kinase/NF-kappaB signaling GO:0007249 9.74 RPS27A ROCK2 ROCK1
11 regulation of circadian rhythm GO:0042752 9.71 TARDBP ROCK2 MTOR
12 negative regulation of neuron death GO:1901215 9.7 LRRK2 GBA CSF3
13 regulation of stress fiber assembly GO:0051492 9.67 ROCK2 ROCK1
14 regulation of keratinocyte differentiation GO:0045616 9.67 ROCK2 ROCK1
15 mitotic cytokinesis GO:0000281 9.67 ROCK2 ROCK1 CFL1
16 mRNA destabilization GO:0061157 9.66 ROCK2 ROCK1
17 negative regulation of macroautophagy GO:0016242 9.65 MTOR LRRK2
18 positive regulation of connective tissue replacement GO:1905205 9.65 ROCK2 ROCK1
19 regulation of synaptic vesicle endocytosis GO:1900242 9.64 ROCK1 LRRK2
20 response to transforming growth factor beta GO:0071559 9.64 ROCK2 ROCK1
21 regulation of protein metabolic process GO:0051246 9.62 ROCK2 GBA
22 regulation of mitochondrial fission GO:0090140 9.6 MAPT LRRK2
23 negative regulation of biomineral tissue development GO:0070168 9.59 ROCK2 ROCK1
24 axonal transport of mitochondrion GO:0019896 9.58 UCHL1 MAPT
25 regulation of establishment of endothelial barrier GO:1903140 9.56 ROCK2 ROCK1
26 intracellular distribution of mitochondria GO:0048312 9.55 MAPT LRRK2
27 regulation of cell junction assembly GO:1901888 9.51 ROCK2 ROCK1
28 lysosome organization GO:0007040 9.5 MTOR LRRK2 GBA
29 response to angiotensin GO:1990776 9.48 ROCK2 ROCK1
30 negative regulation of bicellular tight junction assembly GO:1903347 9.46 ROCK2 ROCK1
31 regulation of autophagy GO:0010506 9.46 ROCK1 MTOR MAPT LRRK2
32 neuron projection arborization GO:0140058 9.43 ROCK1 LRRK2
33 negative regulation of myosin-light-chain-phosphatase activity GO:0035509 9.4 ROCK2 ROCK1
34 regulation of angiotensin-activated signaling pathway GO:0110061 9.26 ROCK2 ROCK1
35 peptidyl-threonine phosphorylation GO:0018107 9.26 ROCK2 ROCK1 MTOR LRRK2
36 peptidyl-serine phosphorylation GO:0018105 9.02 RPS6KB1 ROCK2 ROCK1 MTOR LRRK2

Molecular functions related to Corticobasal Degeneration according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.21 UCHL1 TARDBP SOS1 RPS6KB1 RPS27A ROCK2
2 protein kinase activity GO:0004672 9.77 RPS6KB1 ROCK2 ROCK1 MTOR LRRK2
3 microtubule binding GO:0008017 9.62 MAPT LRRK2 KIF13B CRYAB
4 protein serine/threonine kinase activity GO:0004674 9.55 RPS6KB1 ROCK2 ROCK1 MTOR LRRK2
5 Rho GTPase binding GO:0017048 9.13 ROCK2 ROCK1 LRRK2
6 Rho-dependent protein serine/threonine kinase activity GO:0072518 8.62 ROCK2 ROCK1

Sources for Corticobasal Degeneration

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....